delivered and on while Thank corporate top afternoon, line joining R&D the in quarter, commercial, for goals. strong bottom executing growth third us. We and Good everyone. you development
Xyrem World the submission. positive XX% We sharing candidate at III our novel oxybate preparing and JZP-XXX, progress key product Phase recent our data Sleep in by some sodium Congress highlights. made start with than presented on I'll less NDA
to in redeem the NDA FDA timelines, plan Based approval submit and treatment and to January voucher potential the we JZP-XXX We can for expected next cataplexy XXXX. quarter early priority and of expect review as on as see for our narcolepsy EDS year. review third
launched observing growing interest in We July and are trial, patient US product increasing the Sunosi in access. and in improving prescriptions prescriber
prelaunch this EMA activities We CHMP EU anticipate opinion and as a are month engaged XXXX. early in in positive Sunosi we decision
to FDA Children's the recombinant the protocol Group with pivotal of study for the and finalize Oncology Erwinia the worked our We asparaginase. JZP-XXX,
working year. We target patient first and next this completion are study quarter toward recruiting
leukemia. granted FDA for Recently, designation acute of JZP-XXX the treatment fast-track for lymphoblastic
patients our with in treatment tremor. of also acquisition worldwide Cavion Vyxeos pipeline multiple to and rights clinical and of We development to essential studies we and enrolled strengthen for continued Defitelio CX-XXXX the the potential
drug treatment Now, outside our an to ES We're currently where limited treatment no key I'll and options option the sleep Sunosi of OSA looking for early US there US ES licensed the neuroscience launch bringing and are provide update in our narcolepsy. and patients stages is on for and programs.
experience encouraged We while early, patients, of key for of which, the positive Sunosi rates are and EDS trending from the and opinion the refill awareness received and by positive rising leaders and providers we've treatment growing and pleased healthcare narcolepsy US with in demand in are indicate OSA. feedback patient upward
these clinical continue try their than resulting can third in so unique prescribers there Samples patients and helping more of programs, are experience were resource key than physicians healthcare Sunosi, to During the more providers a gain and will scripts. Sunosi. X,XXX vouchers X,XXX for utilize quarter, by we
who and patients. primarily establish outreach Xyrem expanding existing including to educate those manage beyond with OSA prescribers, prescribers We're relationships new
EDS the quarter, role of completed and of pathophysiology in XXX providing education EDS treating the speaker programs narcolepsy third pharmacotherapy and about the more During and we than peer-to-peer OSA.
consumer by growth a of unique nonbranded kind to awareness different Our campaigns in continue evidenced Sunosi.com. engagement seeing as to tired.com and visits are and raise we strong
Sunosi, a improve of comprehensive appropriate get that help patient costs. out-of-pocket adjudicated lower been of programs to have To patients co-pay $X. have these help experience programs Approximately we resulted with launched patient XX% access scripts through in patient
sleep coverage products. Now, patient I'll strategy optimize current and commercial to discussing formulary. been our that, Sunosi national our Express moment in to added for the has early and preferred launch, We're commercial spend a pleased the Scripts access future
benefit a prior largest one one preferred step for Scripts The therapy including expectations. prelaunch requirement, Tier Express pharmacy agent, the generic consistent X is promoting with status weight authorization managers US. the in our includes of Sunosi of
pleased our commercial are are payer We with coverage actively engaged and contracting discussions payers. other in with today key
growth on volume total Xyrem Now Xyrem. an the to X.X% quarter same had of with period to in XXXX. exceptional compared
force while the period strong sales Xyrem continue able of to to pleased active the Sunosi. same was of We number patients particularly The launching year. are up Xyrem to growth our compared X% expanded average last increased that XX,XXX,
narcolepsy available symptoms. with in EDS educated narcolepsy, both and how and professionals are efforts As treatment patients' children for the our adults on focused healthcare on are only FDA-approved cataplexy cataplexy EDS Xyrem may ensuring and help
current access of executing in we patient the for strategy to During products payer evolving ensure began quarter, ongoing Xyrem our agreements environment. part the and our as to third
Xyrem impact This will have gross some nets. to to
increasing growth, opportunities disease Xyrem, of diagnosis volume However, underdiagnosed as this and continued and growth undertreated in for we narcolepsy population. that efforts both believe are education our awareness and revenue patient
will few at that want Miller, who many today U.S. EVP, is Mike Commercial, – XX more the to to announced today, years, our over Mike role and of industry. Before next years you know on in be than – the management call I XX turn the provide a March I from his after actually, call We updates. retiring Dan, Jazz
years. has six has past team to and Mike built strong the significant Jazz contributions a provided over
Mike's his retirement. search in best all to transition, wish for a beginning successor smooth Mike which a are the ensure we'll soon We after
Additionally, was SVP, to a we great announce of when company. member Head executive in from within Ops. from who management always of new we the Tech team, pleased sourcing promoted Larkin, of leadership the advance pleased recently can we talent Finbar to Along XXXX Jazz, develop outside with joined Jazz and are are and
I'll our the up update call financial update an to I'll now hem/onc will key wrap operational over programs turn Dan an Rob to on Then and our with activities. on performance. you update on provide development
